PAMS
SYRE icon

Pictet Asset Management (Switzerland)’s Spyre Therapeutics SYRE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-101,717
Closed -$1.34M – 2012
2022
Q3 		$1.34M Sell
101,717
-93,903
-48% -$1.16M ﹤0.01% 975
2022
Q2 		$2.47M Buy
195,620
+93,523
+92% +$3.28M ﹤0.01% 908
2022
Q1 		$5.87M Buy
102,097
+3,372
+3% +$283K 0.01% 780
2021
Q4 		$11.7M Sell
98,725
-2,587
-3% -$408K 0.01% 628
2021
Q3 		$20.1M Buy
+101,312
New +$17.7M 0.02% 512

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s SYRE Position: Q4 2022 in Review

Pictet Asset Management (Switzerland) sold out of Spyre Therapeutics (SYRE) in Q4 2022, closing a stake of 101,717 shares — an estimated $1.34M sold.

Pictet Asset Management (Switzerland) first reported a position in SYRE in Q3 2021 and held it in 5 quarters. The position peaked at $20.1M in Q3 2021. 50 funds tracked by Wall St. Rank hold SYRE as of Q4 2022.

  • Pictet Asset Management (Switzerland) reported no remaining Spyre Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 101,717 Spyre Therapeutics shares in Q4 2022, an estimated $1.34M.
  • Pictet Asset Management (Switzerland) first reported a position in Spyre Therapeutics in Q3 2021 and held it in 5 quarters.
  • Pictet Asset Management (Switzerland)'s Spyre Therapeutics position peaked at $20.1M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q4 2022, filed 13 Feb 2023.